fulvestrant
fulvestrant is listed in the FDA National Drug Code directory with 14 NDC codes, marketed under brand names including CLIGAVYX, fulvestrant, FULVESTRANT. Available dosage forms: injection, injection, solution, powder.
Drug details
- Generic Name
- fulvestrant
- Brand Names
- CLIGAVYX, fulvestrant, FULVESTRANT, Fulvestrant
- Application Number
- NDA210063
- Sponsor
- Avyxa Pharma, LLC
- NDC Codes
- 14
- Dosage Forms
- INJECTION, INJECTION, SOLUTION, POWDER
- Routes
- INTRAMUSCULAR
- Active Ingredients
- FULVESTRANT
Indications and Usage
1 INDICATIONS AND USAGE Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.